---
schema_version: "secwatch.filing_event.v1"
accession: "0001516551-24-000059"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2024-06-10T23:59:59+00:00"
generated_at: "2026-06-01T05:17:02.407571+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience Phase 2a trial of SBI-100 OE fails primary endpoint; discontinues ophthalmology program

## Summary
- Phase 2a trial of SBI-100 in 56 patients with POAG or OHT did not meet primary IOP endpoint vs placebo.
- Drug safe; all patients completed study with no early discontinuations due to adverse events.
- Company discontinues all SBI-100 development and ophthalmology pipeline; focuses on obesity program with Nimacimab.
- Phase 2 obesity trial of Nimacimab expected to start Q3 2024; cash runway extended into 2027.

## SEC filing metadata
- accession: 0001516551-24-000059
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2024-06-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000151655124000059/0001516551-24-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000151655124000059/skye-20240610.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001516551-24-000059
- JSON: https://secwatch.observer/filing/0001516551-24-000059.json
- Plain text: https://secwatch.observer/filing/0001516551-24-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.